VRTX
insider transactionsVERTEX PHARMACEUTICALS INC / MA — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-179.1K
0 buy · 179.1K sell
Net value · 365d
-$84.9M
$0 in · $84.9M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
67
0 buy · 179.1K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
EVP and CMO · 10b5-1
$1.8M
4.1K sh · $450.00
Own -19%
-
Sell·S
EVP and CMO · 10b5-1
$785.2K
1.7K sh · $450.00
Own -8%
-
Sell·S
EVP and Chief Legal Officer · 10b5-1
$364.2K
828 sh · $439.91
Own -4%
-
Sell·S
EVP and CMO · 10b5-1
$888.3K
2.0K sh · $450.00
Own -8%
-
Sell·S
EVP, Chief Scientific Officer · 10b5-1
$15.0K
33 sh · $453.45
Own -0%
-
Sell·S
EVP and CMO · 10b5-1
$614.0K
1.4K sh · $453.45
Own -5%
-
Sell·S
EVP and CMO · 10b5-1
$3.1M
7.0K sh · $450.00
Own -21%
-
Sell·S
Director · 10b5-1
$134.7K
318 sh · $423.73
Own -6%
-
Grant·A
Director
—
796 sh
Own +28%
-
Grant·A
Director
$0
2.9K sh
Own New
-
Other·D
Director
—
796 sh
Own -34%
-
Grant·A
Director
—
398 sh
Own New
-
Grant·A
Director
$0
1.4K sh
Own New
-
Other·D
Director
—
398 sh
Own -16%
-
Grant·A
Director
$0
472 sh
Own +23%
-
Grant·A
Director
—
796 sh
Own New
-
Grant·A
Director
$0
1.4K sh
Own New
-
Other·D
Director
—
796 sh
Own -36%
-
Grant·A
Director
$0
472 sh
Own +27%
-
Grant·A
Director
$0
2.9K sh
Own New
-
Sell·S
EVP and Chief Legal Officer · 10b5-1
$469.2K
1.1K sh · $425.02
Own -5%
-
Grant·A
Director
$0
2.9K sh
Own New
-
Grant·A
Director
$0
1.4K sh
Own New
-
Grant·A
Director
$0
472 sh
Own +7%
-
Grant·A
Director
$0
2.9K sh
Own New
-
Grant·A
Director · 10b5-1
$0
943 sh
Own +22%
-
Grant·A
Director
$35.6K
81 sh · $442.50
Own +3%
-
Grant·A
Director
$47.5K
107 sh · $442.50
Own +1%
-
Grant·A
Director
$15.0K
34 sh · $442.50
Own New
-
Sell·S
EVP and Chief Legal Officer · 10b5-1
$439.3K
978 sh · $449.17
Own -4%
-
Sell·S
EVP and CMO · 10b5-1
$1.1M
2.3K sh · $450.95
Own -7%
-
Sell·S
EVP and CMO · 10b5-1
$1.1M
2.3K sh · $481.79
Own -6%
-
Sell·S
Director
$201.3K
650 sh · $309.62
Own -20%
-
Sell·S
EVP, Chief Commercial Officer · 10b5-1
$1.3M
2.6K sh · $498.42
Own -17%
-
Exercise·M
Suketu Upadhyay KEY
Exec VP, CFO
$0
4.6K sh
Own New
-
Exercise·M
Suketu Upadhyay KEY
Exec VP, CFO
$0
10.2K sh
Own New
-
Other·F
Suketu Upadhyay KEY
Exec VP, CFO
$187.8K
2.0K sh · $92.54
Own -3%
-
Exercise·M
Suketu Upadhyay KEY
Exec VP, CFO
$0
4.6K sh
Own +7%
-
Other·F
Suketu Upadhyay KEY
Exec VP, CFO
$420.8K
4.5K sh · $92.54
Own -6%
-
Exercise·M
Suketu Upadhyay KEY
Exec VP, CFO
$0
10.2K sh
Own +17%
-
Sell·S
EVP, Chief Commercial Officer · 10b5-1
$1.2M
2.4K sh · $475.30
Own -14%
-
Sell·S
EVP and Chief Legal Officer · 10b5-1
$442.4K
892 sh · $495.96
Own -4%
-
Other·F
Michel Lagarde KEY
Executive Vice President
$187.5K
360 sh · $521.11
Own -0%
-
Other·F
Michel Lagarde KEY
Executive Vice President
$436.1K
837 sh · $521.11
Own -1%
-
Sell·S
CEO & President · 10b5-1
$857.2K
1.7K sh · $496.95
Own -2%
-
Sell·S
CEO & President · 10b5-1
$3.0M
6.0K sh · $496.16
Own -6%
-
Sell·S
CEO & President · 10b5-1
$7.7M
15.6K sh · $495.38
Own -13%
-
Sell·S
CEO & President · 10b5-1
$1.7M
3.5K sh · $494.33
Own -3%
-
Sell·S
CEO & President · 10b5-1
$1.2M
2.5K sh · $493.29
Own -2%
-
Sell·S
CEO & President · 10b5-1
$466.2K
949 sh · $491.30
Own -1%
-
Sell·S
CEO & President · 10b5-1
$1.3M
2.7K sh · $490.54
Own -2%
-
Sell·S
CEO & President · 10b5-1
$225.1K
460 sh · $489.32
Own -0%
-
Sell·S
CEO & President · 10b5-1
$1.6M
3.3K sh · $488.27
Own -2%
-
Sell·S
CEO & President · 10b5-1
$1.2M
2.5K sh · $487.13
Own -2%
-
Sell·S
CEO & President · 10b5-1
$115.9K
240 sh · $482.84
Own -0%
-
Sell·S
CEO & President · 10b5-1
$57.8K
120 sh · $481.50
Own -0%
-
Sell·S
CEO & President · 10b5-1
$191.9K
400 sh · $479.75
Own -0%
-
Sell·S
EVP and CMO · 10b5-1
$1.1M
2.3K sh · $480.31
Own -6%
-
Sell·S
SVP & Chief Accounting Officer · 10b5-1
$172.6K
357 sh · $483.36
Own -5%
-
Sell·S
EVP, Chief Reg. & Quality Off. · 10b5-1
$126.5K
260 sh · $486.35
Own -1%
-
Sell·S
EVP Chief Patient & Ext Af Off · 10b5-1
$897.8K
1.8K sh · $486.35
Own -3%
-
Sell·S
EVP, Chief Commercial Officer · 10b5-1
$1.2M
2.4K sh · $489.00
Own -12%
-
Sell·S
EVP, Chief Commercial Officer · 10b5-1
$1.2M
2.5K sh · $486.35
Own -11%
-
Sell·S
EVP, Chief Scientific Officer · 10b5-1
$301.5K
620 sh · $486.35
Own -8%
-
Sell·S
EVP and Chief Legal Officer · 10b5-1
$459.6K
945 sh · $486.35
Own -6%
-
Sell·S
EVP, Chief Technical Ops. Off. · 10b5-1
$324.9K
668 sh · $486.35
Own -3%
-
Sell·S
SVP & Chief Accounting Officer · 10b5-1
$108.5K
223 sh · $486.35
Own -3%
-
Exercise·M
Suketu Upadhyay KEY
Exec VP, CFO
$0
6.4K sh
Own +100%
-
Other·F
Suketu Upadhyay KEY
Exec VP, CFO
$281.8K
2.8K sh · $99.51
Own -4%
-
Exercise·M
Suketu Upadhyay KEY
Exec VP, CFO
$0
6.4K sh
Own +11%
-
Grant·A
Michel Lagarde KEY
Executive Vice President & COO
$0
2.2K sh
Own +3%
-
Other·F
EVP, CO & FO
$846.0K
1.7K sh · $485.11
Own -4%
-
Other·F
EVP, Chief Reg. & Quality Off. · 10b5-1
$789.3K
1.6K sh · $485.11
Own -3%
-
Other·F
EVP Chief Patient & Ext Af Off · 10b5-1
$736.4K
1.5K sh · $485.11
Own -3%
-
Other·F
EVP, Chief Commercial Officer · 10b5-1
$423.5K
873 sh · $485.11
Own -4%
-
Other·F
CEO & President
$2.4M
5.0K sh · $485.11
Own -3%
-
Other·F
EVP, Chief Scientific Officer · 10b5-1
$282.3K
582 sh · $485.11
Own -7%
-
Other·F
EVP and CMO
$704.9K
1.5K sh · $485.11
Own -3%
-
Other·F
EVP and Chief Legal Officer · 10b5-1
$555.0K
1.1K sh · $485.11
Own -7%
-
Other·F
EVP, Chief Technical Ops. Off. · 10b5-1
$789.3K
1.6K sh · $485.11
Own -8%
-
Other·F
SVP & Chief Accounting Officer · 10b5-1
$264.9K
546 sh · $485.11
Own -7%
-
Grant·A
Suketu Upadhyay KEY
Exec VP, CFO
$0
21.7K sh
Own New
-
Exercise·M
Suketu Upadhyay KEY
Exec VP, CFO
$0
5.4K sh
Own New
-
Other·F
Suketu Upadhyay KEY
Exec VP, CFO
$241.2K
2.4K sh · $98.62
Own -4%
-
Exercise·M
Suketu Upadhyay KEY
Exec VP, CFO
$0
5.4K sh
Own +10%
-
Grant·A
Suketu Upadhyay KEY
Exec VP, CFO
$0
10.2K sh
Own New
-
Exercise·M
EVP Chief Patient & Ext Af Off · 10b5-1
$0
25.0K sh
Own New
-
Exercise·M
EVP Chief Patient & Ext Af Off · 10b5-1
$0
23.5K sh
Own New
-
Sell·S
EVP Chief Patient & Ext Af Off · 10b5-1
$2.0M
4.2K sh · $471.43
Own -7%
-
Sell·S
EVP Chief Patient & Ext Af Off · 10b5-1
$5.5M
11.7K sh · $470.54
Own -16%
-
Sell·S
EVP Chief Patient & Ext Af Off · 10b5-1
$3.4M
7.2K sh · $469.61
Own -9%
-
Sell·S
EVP Chief Patient & Ext Af Off · 10b5-1
$9.2M
19.7K sh · $468.57
Own -19%
-
Sell·S
EVP Chief Patient & Ext Af Off · 10b5-1
$4.8M
10.3K sh · $467.75
Own -9%
-
Sell·S
EVP Chief Patient & Ext Af Off · 10b5-1
$860.8K
1.8K sh · $465.80
Own -2%
-
Sell·S
EVP Chief Patient & Ext Af Off · 10b5-1
$1.3M
2.7K sh · $465.05
Own -2%
-
Sell·S
EVP Chief Patient & Ext Af Off · 10b5-1
$426.8K
920 sh · $463.91
Own -1%
-
Exercise·M
EVP Chief Patient & Ext Af Off · 10b5-1
$4.7M
25.0K sh · $187.53
Own +27%
-
Exercise·M
EVP Chief Patient & Ext Af Off · 10b5-1
$3.7M
23.5K sh · $155.57
Own +34%
-
Sell·S
EVP, Chief Reg. & Quality Off. · 10b5-1
$174.3K
368 sh · $473.68
Own -1%
-
Sell·S
EVP, Chief Scientific Officer · 10b5-1
$559.9K
1.2K sh · $473.68
Own -12%
-
Sell·S
EVP and Chief Legal Officer · 10b5-1
$589.3K
1.2K sh · $473.68
Own -7%
-
Sell·S
EVP, Chief Technical Ops. Off. · 10b5-1
$387.0K
817 sh · $473.68
Own -4%
-
Sell·S
SVP & Chief Accounting Officer · 10b5-1
$302.2K
638 sh · $473.68
Own -8%
-
Other·F
EVP, CO & FO
$1.1M
2.3K sh · $483.75
Own -4%
-
Grant·A
EVP, CO & FO
$0
7.4K sh
Own +17%
-
Sell·S
EVP, Chief Reg. & Quality Off. · 10b5-1
$298.1K
609 sh · $489.46
Own -1%
-
Other·F
EVP, Chief Reg. & Quality Off. · 10b5-1
$1.1M
2.3K sh · $483.75
Own -4%
-
Grant·A
EVP, Chief Reg. & Quality Off. · 10b5-1
$0
5.8K sh
Own +13%
-
Other·F
EVP Chief Patient & Ext Af Off
$1.0M
2.1K sh · $483.75
Own -3%
-
Grant·A
EVP Chief Patient & Ext Af Off
$0
5.8K sh
Own +9%
-
Other·F
EVP, Chief Commercial Officer
$555.3K
1.1K sh · $483.75
Own -5%
-
Grant·A
EVP, Chief Commercial Officer
$0
5.0K sh
Own +25%
-
Other·F
CEO & President
$3.2M
6.6K sh · $483.75
Own -4%
-
Grant·A
CEO & President
$0
16.3K sh
Own +12%
-
Sell·S
EVP, Chief Scientific Officer · 10b5-1
$1.2M
2.4K sh · $489.46
Own -20%
-
Other·F
EVP, Chief Scientific Officer · 10b5-1
$537.0K
1.1K sh · $483.75
Own -8%
-
Grant·A
EVP, Chief Scientific Officer · 10b5-1
$0
2.6K sh
Own +24%
-
Other·F
EVP and CMO
$924.9K
1.9K sh · $483.75
Own -4%
-
Grant·A
EVP and CMO
$0
5.4K sh
Own +14%
-
Sell·S
EVP and Chief Legal Officer · 10b5-1
$1.2M
2.5K sh · $489.46
Own -13%
-
Other·F
EVP and Chief Legal Officer · 10b5-1
$728.0K
1.5K sh · $483.75
Own -7%
-
Grant·A
EVP and Chief Legal Officer · 10b5-1
$0
4.1K sh
Own +25%
-
Sell·S
EVP, Chief Technical Ops. Off. · 10b5-1
$994.1K
2.0K sh · $489.46
Own -9%
-
Other·F
EVP, Chief Technical Ops. Off. · 10b5-1
$740.1K
1.5K sh · $483.75
Own -6%
-
Grant·A
EVP, Chief Technical Ops. Off. · 10b5-1
$0
5.0K sh
Own +25%
-
Sell·S
SVP & Chief Accounting Officer · 10b5-1
$762.1K
1.6K sh · $489.46
Own -16%
-
Other·F
SVP & Chief Accounting Officer · 10b5-1
$289.3K
598 sh · $483.75
Own -6%
-
Grant·A
SVP & Chief Accounting Officer · 10b5-1
$0
1.8K sh
Own +21%
-
Other·F
EVP, CO & FO
$2.2M
4.6K sh · $487.76
Own -9%
-
Sell·S
EVP, Chief Reg. & Quality Off. · 10b5-1
$750.0K
1.5K sh · $499.99
Own -3%
-
Other·F
EVP, Chief Reg. & Quality Off. · 10b5-1
$1.9M
3.8K sh · $487.76
Own -7%
-
Other·F
EVP Chief Patient & Ext Af Off
$1.7M
3.5K sh · $487.76
Own -5%
-
Other·F
EVP, Chief Commercial Officer
$1.1M
2.3K sh · $487.76
Own -10%
-
Other·F
CEO & President
$6.4M
13.0K sh · $487.76
Own -9%
-
Other·F
EVP, Chief Scientific Officer
$1.1M
2.3K sh · $487.76
Own -18%
-
Other·F
EVP and CMO
$1.9M
3.8K sh · $487.76
Own -9%
-
Sell·S
EVP and Chief Legal Officer · 10b5-1
$493.0K
988 sh · $499.00
Own -6%
-
Other·F
EVP and Chief Legal Officer · 10b5-1
$1.5M
3.0K sh · $487.76
Own -14%
-
Sell·S
Director · 10b5-1
$133.0K
266 sh · $500.00
Own -6%
-
Other·F
EVP, Chief Technical Ops. Off.
$928.2K
1.9K sh · $487.76
Own -9%
-
Other·F
SVP & Chief Accounting Officer
$679.4K
1.4K sh · $487.76
Own -14%
-
Sell·S
EVP, Chief Reg. & Quality Off. · 10b5-1
$214.6K
466 sh · $460.43
Own -1%
-
Sell·S
EVP, Chief Scientific Officer · 10b5-1
$930.5K
2.0K sh · $460.43
Own -14%
-
Sell·S
EVP and Chief Legal Officer · 10b5-1
$886.3K
1.9K sh · $460.43
Own -8%
-
Sell·S
EVP, Chief Technical Ops. Off. · 10b5-1
$806.2K
1.8K sh · $460.43
Own -7%
-
Sell·S
SVP & Chief Accounting Officer · 10b5-1
$633.6K
1.4K sh · $460.43
Own -12%
-
Other·F
EVP, CO & FO
$1.4M
3.0K sh · $468.41
Own -6%
-
Other·F
EVP, Chief Reg. & Quality Off. · 10b5-1
$1.0M
2.1K sh · $468.41
Own -4%
-
Other·F
EVP Chief Patient & Ext Af Off
$963.5K
2.1K sh · $468.41
Own -3%
-
Other·F
EVP, Chief Commercial Officer
$527.9K
1.1K sh · $468.41
Own -5%
-
Other·F
CEO & President
$3.9M
8.3K sh · $468.41
Own -5%
-
Other·F
EVP, Chief Scientific Officer · 10b5-1
$527.9K
1.1K sh · $468.41
Own -7%
-
Other·F
EVP and CMO
$1.0M
2.1K sh · $468.41
Own -5%
-
Other·F
EVP and Chief Legal Officer · 10b5-1
$763.5K
1.6K sh · $468.41
Own -7%
-
Other·F
EVP, Chief Technical Ops. Off. · 10b5-1
$408.5K
872 sh · $468.41
Own -4%
-
Other·F
SVP & Chief Accounting Officer · 10b5-1
$277.3K
592 sh · $468.41
Own -5%
-
Grant·A
Director
$0
861 sh
Own +35%
-
Grant·A
EVP, CO & FO
$0
4.2K sh
Own +9%
-
Grant·A
EVP, CO & FO
$0
9.4K sh
Own +25%
-
Grant·A
EVP, Chief Reg. & Quality Off.
$0
3.9K sh
Own +8%
-
Grant·A
EVP, Chief Reg. & Quality Off.
$0
7.9K sh
Own +19%
-
Grant·A
EVP Chief Patient & Ext Af Off
$0
3.9K sh
Own +6%
-
Grant·A
EVP Chief Patient & Ext Af Off
$0
7.9K sh
Own +13%
-
Grant·A
EVP, Chief Commercial Officer
$0
2.1K sh
Own +10%
-
Grant·A
EVP, Chief Commercial Officer
$0
4.7K sh
Own +29%
-
Grant·A
CEO & President
$0
11.9K sh
Own +8%
-
Grant·A
CEO & President
$0
27.0K sh
Own +23%
-
Grant·A
EVP and CMO
$0
3.5K sh
Own +9%
-
Grant·A
EVP and CMO
$0
7.9K sh
Own +24%
-
Grant·A
EVP and Chief Legal Officer
$0
2.8K sh
Own +13%
-
Grant·A
EVP and Chief Legal Officer
$0
6.3K sh
Own +41%
-
Grant·A
EVP, Chief Technical Ops. Off.
$0
3.9K sh
Own +19%
-
Grant·A
EVP, Chief Technical Ops. Off.
$0
3.9K sh
Own +23%
-
Grant·A
SVP & Chief Accounting Officer
$0
1.3K sh
Own +12%
-
Grant·A
SVP & Chief Accounting Officer
$0
3.0K sh
Own +38%
-
Grant·A
EVP, Chief Scientific Officer
$0
3.3K sh
Own +11%
-
Grant·A
EVP, Chief Scientific Officer
$0
7.9K sh
Own +34%
-
Grant·A
Director
$35.6K
80 sh · $443.56
Own +3%
-
Grant·A
Director
$47.5K
107 sh · $443.56
Own +1%
-
Sell·S
EVP, Chief Reg. & Quality Off. · 10b5-1
$2.1M
4.5K sh · $474.99
Own -10%
-
Exercise·M
EVP, CO & FO · 10b5-1
$0
9.5K sh
Own New
-
Sell·S
EVP, CO & FO · 10b5-1
$4.4M
9.5K sh · $461.00
Own -20%
-
Exercise·M
EVP, CO & FO · 10b5-1
$1.8M
9.5K sh · $189.38
Own +25%
-
Grant·A
Director
$0
2.3K sh
Own +0%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Carmen Bozic 10b5-1 | Sell S | 4.1K | $1.8M |
| Jun 5, 2026 | Carmen Bozic 10b5-1 | Sell S | 1.7K | $785.2K |
| Jun 1, 2026 | Joy Liu 10b5-1 | Sell S | 828 | $364.2K |
| May 29, 2026 | Carmen Bozic 10b5-1 | Sell S | 2.0K | $888.3K |
| May 15, 2026 | Mark E. Bunnage 10b5-1 | Sell S | 33 | $15.0K |
| May 15, 2026 | Carmen Bozic 10b5-1 | Sell S | 1.4K | $614.0K |
| May 12, 2026 | Carmen Bozic 10b5-1 | Sell S | 7.0K | $3.1M |
| May 4, 2026 | Sangeeta N. Bhatia 10b5-1 | Sell S | 318 | $134.7K |
| May 1, 2026 | Suketu Upadhyay | Grant A | 796 | — |
| May 1, 2026 | Suketu Upadhyay | Grant A | 2.9K | $0 |
| May 1, 2026 | Suketu Upadhyay | Other D | 796 | — |
| May 1, 2026 | Nancy Thornberry | Grant A | 398 | — |
| May 1, 2026 | Nancy Thornberry | Grant A | 1.4K | $0 |
| May 1, 2026 | Nancy Thornberry | Other D | 398 | — |
| May 1, 2026 | Nancy Thornberry | Grant A | 472 | $0 |
| May 1, 2026 | Jennifer Schneider | Grant A | 796 | — |
| May 1, 2026 | Jennifer Schneider | Grant A | 1.4K | $0 |
| May 1, 2026 | Jennifer Schneider | Other D | 796 | — |
| May 1, 2026 | Jennifer Schneider | Grant A | 472 | $0 |
| May 1, 2026 | Bruce I Sachs | Grant A | 2.9K | $0 |
| May 1, 2026 | Joy Liu 10b5-1 | Sell S | 1.1K | $469.2K |
| May 1, 2026 | Michel Lagarde | Grant A | 2.9K | $0 |
| May 1, 2026 | Alan M Garber | Grant A | 1.4K | $0 |
| May 1, 2026 | Alan M Garber | Grant A | 472 | $0 |
| May 1, 2026 | Lloyd Carney | Grant A | 2.9K | $0 |
| May 1, 2026 | Sangeeta N. Bhatia 10b5-1 | Grant A | 943 | $0 |
| Apr 15, 2026 | Suketu Upadhyay | Grant A | 81 | $35.6K |
| Apr 15, 2026 | Bruce I Sachs | Grant A | 107 | $47.5K |
| Apr 15, 2026 | Alan M Garber | Grant A | 34 | $15.0K |
| Apr 1, 2026 | Joy Liu 10b5-1 | Sell S | 978 | $439.3K |
| Mar 27, 2026 | Carmen Bozic 10b5-1 | Sell S | 2.3K | $1.1M |
| Mar 13, 2026 | Carmen Bozic 10b5-1 | Sell S | 2.3K | $1.1M |
| Mar 11, 2026 | Lloyd Carney | Sell S | 650 | $201.3K |
| Mar 11, 2026 | Duncan Mckechnie 10b5-1 | Sell S | 2.6K | $1.3M |
| Mar 6, 2026 | Suketu Upadhyay KEY | Exercise M | 4.6K | $0 |
| Mar 6, 2026 | Suketu Upadhyay KEY | Exercise M | 10.2K | $0 |
| Mar 6, 2026 | Suketu Upadhyay KEY | Other F | 2.0K | $187.8K |
| Mar 6, 2026 | Suketu Upadhyay KEY | Exercise M | 4.6K | $0 |
| Mar 6, 2026 | Suketu Upadhyay KEY | Other F | 4.5K | $420.8K |
| Mar 6, 2026 | Suketu Upadhyay KEY | Exercise M | 10.2K | $0 |
| Mar 4, 2026 | Duncan Mckechnie 10b5-1 | Sell S | 2.4K | $1.2M |
| Mar 2, 2026 | Joy Liu 10b5-1 | Sell S | 892 | $442.4K |
| Feb 28, 2026 | Michel Lagarde KEY | Other F | 360 | $187.5K |
| Feb 28, 2026 | Michel Lagarde KEY | Other F | 837 | $436.1K |
| Feb 27, 2026 | Reshma Kewalramani KEY 10b5-1 | Sell S | 1.7K | $857.2K |
| Feb 27, 2026 | Reshma Kewalramani KEY 10b5-1 | Sell S | 6.0K | $3.0M |
| Feb 27, 2026 | Reshma Kewalramani KEY 10b5-1 | Sell S | 15.6K | $7.7M |
| Feb 27, 2026 | Reshma Kewalramani KEY 10b5-1 | Sell S | 3.5K | $1.7M |
| Feb 27, 2026 | Reshma Kewalramani KEY 10b5-1 | Sell S | 2.5K | $1.2M |
| Feb 27, 2026 | Reshma Kewalramani KEY 10b5-1 | Sell S | 949 | $466.2K |
| Feb 27, 2026 | Reshma Kewalramani KEY 10b5-1 | Sell S | 2.7K | $1.3M |
| Feb 27, 2026 | Reshma Kewalramani KEY 10b5-1 | Sell S | 460 | $225.1K |
| Feb 27, 2026 | Reshma Kewalramani KEY 10b5-1 | Sell S | 3.3K | $1.6M |
| Feb 27, 2026 | Reshma Kewalramani KEY 10b5-1 | Sell S | 2.5K | $1.2M |
| Feb 27, 2026 | Reshma Kewalramani KEY 10b5-1 | Sell S | 240 | $115.9K |
| Feb 27, 2026 | Reshma Kewalramani KEY 10b5-1 | Sell S | 120 | $57.8K |
| Feb 27, 2026 | Reshma Kewalramani KEY 10b5-1 | Sell S | 400 | $191.9K |
| Feb 27, 2026 | Carmen Bozic 10b5-1 | Sell S | 2.3K | $1.1M |
| Feb 26, 2026 | Kristen Ambrose 10b5-1 | Sell S | 357 | $172.6K |
| Feb 25, 2026 | Ourania Tatsis 10b5-1 | Sell S | 260 | $126.5K |
| Feb 25, 2026 | Amit Sachdev 10b5-1 | Sell S | 1.8K | $897.8K |
| Feb 25, 2026 | Duncan Mckechnie 10b5-1 | Sell S | 2.4K | $1.2M |
| Feb 25, 2026 | Duncan Mckechnie 10b5-1 | Sell S | 2.5K | $1.2M |
| Feb 25, 2026 | Mark E. Bunnage 10b5-1 | Sell S | 620 | $301.5K |
| Feb 25, 2026 | Jonathan Biller 10b5-1 | Sell S | 945 | $459.6K |
| Feb 25, 2026 | Edward Morrow Atkinson III 10b5-1 | Sell S | 668 | $324.9K |
| Feb 25, 2026 | Kristen Ambrose 10b5-1 | Sell S | 223 | $108.5K |
| Feb 25, 2026 | Suketu Upadhyay KEY | Exercise M | 6.4K | $0 |
| Feb 25, 2026 | Suketu Upadhyay KEY | Other F | 2.8K | $281.8K |
| Feb 25, 2026 | Suketu Upadhyay KEY | Exercise M | 6.4K | $0 |
| Feb 25, 2026 | Michel Lagarde KEY | Grant A | 2.2K | $0 |
| Feb 24, 2026 | Charles F Wagner JR | Other F | 1.7K | $846.0K |
| Feb 24, 2026 | Ourania Tatsis 10b5-1 | Other F | 1.6K | $789.3K |
| Feb 24, 2026 | Amit Sachdev 10b5-1 | Other F | 1.5K | $736.4K |
| Feb 24, 2026 | Duncan Mckechnie 10b5-1 | Other F | 873 | $423.5K |
| Feb 24, 2026 | Reshma Kewalramani KEY | Other F | 5.0K | $2.4M |
| Feb 24, 2026 | Mark E. Bunnage 10b5-1 | Other F | 582 | $282.3K |
| Feb 24, 2026 | Carmen Bozic | Other F | 1.5K | $704.9K |
| Feb 24, 2026 | Jonathan Biller 10b5-1 | Other F | 1.1K | $555.0K |
| Feb 24, 2026 | Edward Morrow Atkinson III 10b5-1 | Other F | 1.6K | $789.3K |
| Feb 24, 2026 | Kristen Ambrose 10b5-1 | Other F | 546 | $264.9K |
| Feb 20, 2026 | Suketu Upadhyay KEY | Grant A | 21.7K | $0 |
| Feb 20, 2026 | Suketu Upadhyay KEY | Exercise M | 5.4K | $0 |
| Feb 20, 2026 | Suketu Upadhyay KEY | Other F | 2.4K | $241.2K |
| Feb 20, 2026 | Suketu Upadhyay KEY | Exercise M | 5.4K | $0 |
| Feb 19, 2026 | Suketu Upadhyay KEY | Grant A | 10.2K | $0 |
| Feb 19, 2026 | Amit Sachdev 10b5-1 | Exercise M | 25.0K | $0 |
| Feb 19, 2026 | Amit Sachdev 10b5-1 | Exercise M | 23.5K | $0 |
| Feb 19, 2026 | Amit Sachdev 10b5-1 | Sell S | 4.2K | $2.0M |
| Feb 19, 2026 | Amit Sachdev 10b5-1 | Sell S | 11.7K | $5.5M |
| Feb 19, 2026 | Amit Sachdev 10b5-1 | Sell S | 7.2K | $3.4M |
| Feb 19, 2026 | Amit Sachdev 10b5-1 | Sell S | 19.7K | $9.2M |
| Feb 19, 2026 | Amit Sachdev 10b5-1 | Sell S | 10.3K | $4.8M |
| Feb 19, 2026 | Amit Sachdev 10b5-1 | Sell S | 1.8K | $860.8K |
| Feb 19, 2026 | Amit Sachdev 10b5-1 | Sell S | 2.7K | $1.3M |
| Feb 19, 2026 | Amit Sachdev 10b5-1 | Sell S | 920 | $426.8K |
| Feb 19, 2026 | Amit Sachdev 10b5-1 | Exercise M | 25.0K | $4.7M |
| Feb 19, 2026 | Amit Sachdev 10b5-1 | Exercise M | 23.5K | $3.7M |
| Feb 18, 2026 | Ourania Tatsis 10b5-1 | Sell S | 368 | $174.3K |
| Feb 18, 2026 | Mark E. Bunnage 10b5-1 | Sell S | 1.2K | $559.9K |
| Feb 18, 2026 | Jonathan Biller 10b5-1 | Sell S | 1.2K | $589.3K |
| Feb 18, 2026 | Edward Morrow Atkinson III 10b5-1 | Sell S | 817 | $387.0K |
| Feb 18, 2026 | Kristen Ambrose 10b5-1 | Sell S | 638 | $302.2K |
| Feb 17, 2026 | Charles F Wagner JR | Other F | 2.3K | $1.1M |
| Feb 17, 2026 | Charles F Wagner JR | Grant A | 7.4K | $0 |
| Feb 17, 2026 | Ourania Tatsis 10b5-1 | Sell S | 609 | $298.1K |
| Feb 17, 2026 | Ourania Tatsis 10b5-1 | Other F | 2.3K | $1.1M |
| Feb 17, 2026 | Ourania Tatsis 10b5-1 | Grant A | 5.8K | $0 |
| Feb 17, 2026 | Amit Sachdev | Other F | 2.1K | $1.0M |
| Feb 17, 2026 | Amit Sachdev | Grant A | 5.8K | $0 |
| Feb 17, 2026 | Duncan Mckechnie | Other F | 1.1K | $555.3K |
| Feb 17, 2026 | Duncan Mckechnie | Grant A | 5.0K | $0 |
| Feb 17, 2026 | Reshma Kewalramani KEY | Other F | 6.6K | $3.2M |
| Feb 17, 2026 | Reshma Kewalramani KEY | Grant A | 16.3K | $0 |
| Feb 17, 2026 | Mark E. Bunnage 10b5-1 | Sell S | 2.4K | $1.2M |
| Feb 17, 2026 | Mark E. Bunnage 10b5-1 | Other F | 1.1K | $537.0K |
| Feb 17, 2026 | Mark E. Bunnage 10b5-1 | Grant A | 2.6K | $0 |
| Feb 17, 2026 | Carmen Bozic | Other F | 1.9K | $924.9K |
| Feb 17, 2026 | Carmen Bozic | Grant A | 5.4K | $0 |
| Feb 17, 2026 | Jonathan Biller 10b5-1 | Sell S | 2.5K | $1.2M |
| Feb 17, 2026 | Jonathan Biller 10b5-1 | Other F | 1.5K | $728.0K |
| Feb 17, 2026 | Jonathan Biller 10b5-1 | Grant A | 4.1K | $0 |
| Feb 17, 2026 | Edward Morrow Atkinson III 10b5-1 | Sell S | 2.0K | $994.1K |
| Feb 17, 2026 | Edward Morrow Atkinson III 10b5-1 | Other F | 1.5K | $740.1K |
| Feb 17, 2026 | Edward Morrow Atkinson III 10b5-1 | Grant A | 5.0K | $0 |
| Feb 17, 2026 | Kristen Ambrose 10b5-1 | Sell S | 1.6K | $762.1K |
| Feb 17, 2026 | Kristen Ambrose 10b5-1 | Other F | 598 | $289.3K |
| Feb 17, 2026 | Kristen Ambrose 10b5-1 | Grant A | 1.8K | $0 |
| Feb 13, 2026 | Charles F Wagner JR | Other F | 4.6K | $2.2M |
| Feb 13, 2026 | Ourania Tatsis 10b5-1 | Sell S | 1.5K | $750.0K |
| Feb 13, 2026 | Ourania Tatsis 10b5-1 | Other F | 3.8K | $1.9M |
| Feb 13, 2026 | Amit Sachdev | Other F | 3.5K | $1.7M |
| Feb 13, 2026 | Duncan Mckechnie | Other F | 2.3K | $1.1M |
| Feb 13, 2026 | Reshma Kewalramani KEY | Other F | 13.0K | $6.4M |
| Feb 13, 2026 | Mark E. Bunnage | Other F | 2.3K | $1.1M |
| Feb 13, 2026 | Carmen Bozic | Other F | 3.8K | $1.9M |
| Feb 13, 2026 | Jonathan Biller 10b5-1 | Sell S | 988 | $493.0K |
| Feb 13, 2026 | Jonathan Biller 10b5-1 | Other F | 3.0K | $1.5M |
| Feb 13, 2026 | Sangeeta N. Bhatia 10b5-1 | Sell S | 266 | $133.0K |
| Feb 13, 2026 | Edward Morrow Atkinson III | Other F | 1.9K | $928.2K |
| Feb 13, 2026 | Kristen Ambrose | Other F | 1.4K | $679.4K |
| Feb 11, 2026 | Ourania Tatsis 10b5-1 | Sell S | 466 | $214.6K |
| Feb 11, 2026 | Mark E. Bunnage 10b5-1 | Sell S | 2.0K | $930.5K |
| Feb 11, 2026 | Jonathan Biller 10b5-1 | Sell S | 1.9K | $886.3K |
| Feb 11, 2026 | Edward Morrow Atkinson III 10b5-1 | Sell S | 1.8K | $806.2K |
| Feb 11, 2026 | Kristen Ambrose 10b5-1 | Sell S | 1.4K | $633.6K |
| Feb 10, 2026 | Charles F Wagner JR | Other F | 3.0K | $1.4M |
| Feb 10, 2026 | Ourania Tatsis 10b5-1 | Other F | 2.1K | $1.0M |
| Feb 10, 2026 | Amit Sachdev | Other F | 2.1K | $963.5K |
| Feb 10, 2026 | Duncan Mckechnie | Other F | 1.1K | $527.9K |
| Feb 10, 2026 | Reshma Kewalramani KEY | Other F | 8.3K | $3.9M |
| Feb 10, 2026 | Mark E. Bunnage 10b5-1 | Other F | 1.1K | $527.9K |
| Feb 10, 2026 | Carmen Bozic | Other F | 2.1K | $1.0M |
| Feb 10, 2026 | Jonathan Biller 10b5-1 | Other F | 1.6K | $763.5K |
| Feb 10, 2026 | Edward Morrow Atkinson III 10b5-1 | Other F | 872 | $408.5K |
| Feb 10, 2026 | Kristen Ambrose 10b5-1 | Other F | 592 | $277.3K |
| Jan 27, 2026 | Lloyd Carney | Grant A | 861 | $0 |
| Jan 22, 2026 | Charles F Wagner JR | Grant A | 4.2K | $0 |
| Jan 22, 2026 | Charles F Wagner JR | Grant A | 9.4K | $0 |
| Jan 22, 2026 | Ourania Tatsis | Grant A | 3.9K | $0 |
| Jan 22, 2026 | Ourania Tatsis | Grant A | 7.9K | $0 |
| Jan 22, 2026 | Amit Sachdev | Grant A | 3.9K | $0 |
| Jan 22, 2026 | Amit Sachdev | Grant A | 7.9K | $0 |
| Jan 22, 2026 | Duncan Mckechnie | Grant A | 2.1K | $0 |
| Jan 22, 2026 | Duncan Mckechnie | Grant A | 4.7K | $0 |
| Jan 22, 2026 | Reshma Kewalramani KEY | Grant A | 11.9K | $0 |
| Jan 22, 2026 | Reshma Kewalramani KEY | Grant A | 27.0K | $0 |
| Jan 22, 2026 | Carmen Bozic | Grant A | 3.5K | $0 |
| Jan 22, 2026 | Carmen Bozic | Grant A | 7.9K | $0 |
| Jan 22, 2026 | Jonathan Biller | Grant A | 2.8K | $0 |
| Jan 22, 2026 | Jonathan Biller | Grant A | 6.3K | $0 |
| Jan 22, 2026 | Edward Morrow Atkinson III | Grant A | 3.9K | $0 |
| Jan 22, 2026 | Edward Morrow Atkinson III | Grant A | 3.9K | $0 |
| Jan 22, 2026 | Kristen Ambrose | Grant A | 1.3K | $0 |
| Jan 22, 2026 | Kristen Ambrose | Grant A | 3.0K | $0 |
| Jan 22, 2026 | David Altshuler | Grant A | 3.3K | $0 |
| Jan 22, 2026 | David Altshuler | Grant A | 7.9K | $0 |
| Jan 15, 2026 | Suketu Upadhyay | Grant A | 80 | $35.6K |
| Jan 15, 2026 | Bruce I Sachs | Grant A | 107 | $47.5K |
| Jan 7, 2026 | Ourania Tatsis 10b5-1 | Sell S | 4.5K | $2.1M |
| Jan 6, 2026 | Charles F Wagner JR 10b5-1 | Exercise M | 9.5K | $0 |
| Jan 6, 2026 | Charles F Wagner JR 10b5-1 | Sell S | 9.5K | $4.4M |
| Jan 6, 2026 | Charles F Wagner JR 10b5-1 | Exercise M | 9.5K | $1.8M |
| Dec 23, 2025 | Lloyd Carney | Grant A | 2.3K | $0 |
About VRTX insider trading
This page tracks insider transactions for VERTEX PHARMACEUTICALS INC / MA (VRTX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.